Natural history of imatinib-naive gists: A retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables

American Journal of Surgical Pathology

Volumn 35, Issue 11, 2011, Pages 1646-1656

  Rossi, Sabrina ^a   Miceli, Rosalba ^b   Messerini, Luca ^c   Bearzi, Italo ^d   Mazzoleni, Guido ^e   Capella, Carlo ^b   Arrigoni, Gianluigi ^f   Sonzogni, Aurelio ^g   Sidoni, Angelo ^h   Toffolatti, Luisa ^a   Laurino, Licia ^a   Mariani, Luigi ^b   Vinaccia, Vincenza ⁱ   Gnocchi, Chiara ⁱ   Gronchi, Alessandro ^j   Casali, Paolo G ^k   Dei Tos, Angelo P ^a  

^a Treviso General Hospital   (Italy)

^b Department of Statistics ^*  (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d University of Marche   (Italy)

^e GENERAL HOSPITAL   (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g OSPEDALI RIUNITI   (Italy)

^h UNIVERSITY OF PERUGIA   (Italy)

ⁱ Novartis Pharma   (Italy)

^j Sarcoma Unit   (Italy)

^k Istituto Nazionale Tumori   (Italy)

more..

Author keywords

GISTs; natural history; nomogram; risk assessment

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHEMISTRY; CHI SQUARE DISTRIBUTION; CHILD; CLINICAL TRIAL; DISEASE COURSE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; ITALY; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MITOSIS INDEX; MORTALITY; MULTICENTER STUDY; NOMOGRAM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TIME; TUMOR VOLUME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHI-SQUARE DISTRIBUTION; CHILD; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MITOTIC INDEX; NOMOGRAMS; PIPERAZINES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TUMOR BURDEN; YOUNG ADULT;

EID: 80054971913     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31822d63a7     Document Type: Article

References (35)

1. Agaimy A, Terracciano LM, Dirnhofer S, et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol. 2009;62:613-616.
2. Agaram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008;47:853-859.
3. Akaike H. Information theory and an extension of the maximum likelihood principle. In: Patrov BN, Csaki F, eds. Proc 2nd Int Symp on Information Theory. Budapest: Akademia Kiedo; 1973:267.
4. DeMatteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008; 112:608-615. (Pubitemid 351186201)
5. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007;5:S1-S29.
6. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8:551-561. (Pubitemid 19116001)
7. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101-121.
8. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459-465. (Pubitemid 34747864)
9. Gasparotto D, Rossi S, Bearzi I, et al. Multiple primary sporadic gastrointestinal stromal tumors in the adult: an underestimated entity. Clin Cancer Res. 2008;14:5715-5721.
10. Goettsch WG, Bos SD, Breekveldt-Postma N, et al. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005;41:2868-2872. (Pubitemid 41713125)
11. Gold JS, Gonen M, Gutierrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resectionm of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10: 1045-1052.
12. Harrell FE Jr, Lee KL, Califf RM, et al. Regression modelling strategies for improved prognostic prediction. Stat Med. 1984;13: 143-152. (Pubitemid 14052973)
13. Hirota S, Isozaki K, Moriyaman Y, et al. Gain-of-Function Mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580. (Pubitemid 28067289)
14. Hostein I, Faur N, Primois C, et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol. 2010;133:141-148.
15. Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26: 1364-1370.
16. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411-1419.
17. Kramer K, Hasel C, Aschoff AJ, et al. Multiple gastrointestinal stromal tumors and bilateral pheochromocytoma in neurofibromatosis. World J Gastroenterol. 2007;13:3384-3387. (Pubitemid 47062252)
18. Lisewski D, Ryan S, Lim EM, et al. Concomitant compostite adrenal phoechromocytoma, multiple gastric stromal tumours and pseudohermaphrodism in a patient with von Recklinghausen's disease. Int Semin Surg Oncol. 2006;3:11.
19. Llenas-Garc?a J, Guerra-Vales JM, Moreno A, et al. Primary extragastrointestinal stromal tumors in the omentum and mesentery: a clinicopathological and immunohistochemical study. Hepatogastroenterology. 2008;55:1002-1005. (Pubitemid 351975974)
20. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:70-83. (Pubitemid 44692418)
21. Miettinen M, Monihan JM, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol. 1999;23:1109-1118. (Pubitemid 29409774)
22. Miettinen M, Sarlomo-Rikala M, Sobin LH, et al. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol. 2000;24:1339-1352.
23. Miettinen M, Furlong M, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol. 2001;25:1121-1133. (Pubitemid 32777711)
24. Miettinen M, Sobin LH, Asota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29:52-68. (Pubitemid 40023952)
25. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors presenting as omental masses: a clinicopathologic analysis of 95 cases. Am J Surg Pathol. 2009;33:1267-1275.
26. Nilsson B, Bu?mming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a populationbased study in western Sweden. Cancer. 2005;103:821-829. (Pubitemid 40216412)
27. Reith JD, Goldblum JR, Lyles RH, et al. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol. 2000;13:577-585. (Pubitemid 30332111)
28. Rizzo S, Bonomo S, Moser A, et al. Bilateral pheochromocytoma associated with duodeno-jejunal GIST in patient with von Recklinghausen disease: report of a clinical case. Chir Ital. 2001;53:243-246.
29. Rossi S, Gasparotto D, Toffolatti L, et al. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34:1480-1491.
30. Stare J, Pohar M. An individual measure of relative survival. Appl Statist. 2005;54:115-126. (Pubitemid 40166925)
31. Steigen SE, Eide TJ, Wasag B, et al. Mutations in gastrointestinal stromal tumors: a population-based study from Northern Norway. APMIS.115; 2007:289-298. (Pubitemid 46743943)
32. Teramoto S, Ota T, Maniwa A, et al. Two von Recklinghausen's disease cases with pheochromocytomas and gastrointestinal stromal tumors (GIST) in combination. Int J Urol. 2007;14:73-74. (Pubitemid 44952586)
33. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1458 cases from 1992 to 2000. Am J Gastroenterol. 2005;100:162-168. (Pubitemid 41623284)
34. Tryggvason G, G?slason HG, Magnu sson MK, et al. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer. 2005;117:289-293. (Pubitemid 41377450)
35. Tworek JA, Goldblum JR, Weiss SW, et al. Stromal tumors of the anorectum: a clinicopathologic study of 22 cases. Am J Surg Pathol. 1999;23:946-954. (Pubitemid 29360113)